Abstract:Background: Irritable bowel syndrome-diarrhoea (IBS-D) and IBS-mixed stool pattern (IBS-M) are disorders of gut-brain interaction characterised by abdominal pain associated with diarrhoea or both diarrhoea and constipation respectively. The pathophysiology of IBS-D/M is multifactorial and not completely understood; thus, treatment is aimed at multiple mechanisms such as altering gut microbiota, visceral hypersensitivity, intestinal permeability, gut-brain interaction and psychological strategies. Aim: The goal of this article was to provide an up-to-date review of the current evidence for both non-pharmacological and pharmacological treatment options in IBS-D and IBS-M. Future treatments for IBS-D and IBS-M will also be discussed. Methods: Medline and Embase database searches (through April 30 2021) to identify clinical studies in subjects with IBS-D in which dietary modification, alternative treatments (probiotics, acupuncture, exercise) as well as FDA-approved medications were used. Results: Dietary modification is often the first line of therapy. Furthermore, lifestyle treatments include complementary alternative medications (CAM), probiotics and peppermint oil are useful adjuncts but have not specifically been described in IBS-D/M. Evidence strongly supports psychotherapy in the treatment of IBS. Beyond over-the counter anti-diarrhoeals, anti-spasmodics and anti-depressants, pharmacological treatment now includes treating for bile acid malabsorption and the FDA-approved medications rifaximin, eluxadoline and alosetron. Conclusions: The treatment of IBS-D/M ideally involves a multidisciplinary approach of primary care, gastroenterologist and psychologist. Treatment often involves both non-pharmacological and pharmacological therapies. Future therapies may include faecal microbial transplant, Crofelemer and serotonin antagonists, but further studies are needed.

The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy

Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome

Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome

Gut Microbiota and Irritable Bowel Syndrome: Status and Prospect

Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome

Microbiome and Its Role in Irritable Bowel Syndrome

Gut–Brain Axis, Microbiota and Probiotics—Current Knowledge on Their Role in Irritable Bowel Syndrome: A Review

Analysis of the status of intestinal microecology and irritable bowel syndrome

The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome

Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects Against Irritable Bowel Syndrome

Gut Microbial Metabolites and Biochemical Pathways Involved in Irritable Bowel Syndrome: Effects of Diet and Nutrition on the Microbiome

Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions

Targeting the gut-microbiota-brain axis in irritable bowel disease to improve cognitive function - recent knowledge and emerging therapeutic opportunities

Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome

Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review

Antibiotics and Probiotics for Irritable Bowel Syndrome

Irritable Bowel Syndrome: Treating the Gut and Brain/Mind at the Same Time

The role of diet in the pathophysiology and management of irritable bowel syndrome

Enteric Microbiota-Mediated Serotonergic Signaling in Pathogenesis of Irritable Bowel Syndrome

Targeting the Microbiota, From Irritable Bowel Syndrome to Mood Disorders: Focus on Probiotics and Prebiotics

Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M)